ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ BỆNH NHÂN LYMPHOMA THỂ NANG VỚI PHÁC ĐỒ CÓ RITUXIMAB SAU 7 NĂM TẠI KHOA HUYẾT HỌC BỆNH VIỆN CHỢ RẪY

Abstract

Objectives: To evaluate the treatment effect of follicular lymphoma patients with rituximab-containing regimen at the Department of Hematology, Cho Ray Hospital from 2014 to 2021. Subjects and methods: Descriptive, prospective, and retrospective study of a series of CD20 (+) follicular lymphoma patients diagnosed and treated according to rituximab-containing regimens at the Department of Hematology - Chong Hospital from January 2014 to July 2021. Results: Through the study of 54 patients with follicular lymphoma, we initially recorded the following results: the mean age of the patient was 54 years old (from 26 to 83 years old). Male/Female ratio: 1:1.08. The majority of patients hospitalized in the late stage of disease (stage III-IV - 72,2%). Classification of risk according to FLIPI: low, medium, and high-risk groups are 22,2%, 29,6%, and 48,1%, respectively. Patients with B symptoms accounted for 59,3%. The disease manifests mainly in the lymph nodes (72,2%), the spleen (25,9%), marrow invasion (20,4%), and in other organs: duodenum, small intestine, large intestine, cavity ophthalmic. All patients were treated with rituximab-containing regimen including RCHOP (72,2%), RB (20,4%), RCVP (3,7%) and Rituximab monotherapy (3,7%). Overall response rate was 98,1% (complete response - CR was 79,6%, partial response - PR was 18,5%). The mean overall survival time was 71,5 months ± 4,3 months. The 7-year overall survival probability is 73,3 % ± 8,1%. The mean progression-free survival was 34,4 months (4 months – 84 months). The probability of 7-year progression-free survival was 49,1% ± 1,19%. Conclusion: The treatment of follicular lymphoma patients with rituximab-containing regimen achieved a high response rate.